Home Newsfeeds U.S. Regulator Says Traffic Deaths Cost United States $340B In 2019

U.S. Regulator Says Traffic Deaths Cost United States $340B In 2019

-Government Study

byBenzinga Newsdesk

January 10, 2023

1 minute read

-Government Study

Discontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In Millions

By Nabaparna Bhattacharya

September 20, 2:29 PM

Needham analyst Serge Belanger reiterated a Buy rating on Revance Therapeutics, Inc. (NASDAQ: RVNC),

RVNC

What’s Going On With Stoke Therapeutics Stock Tuesday?

By Adam Eckert

March 26, 4:54 PM

After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a 30-day window to purchase up to an additional 15% of the shares in the public offering.

STOK

Wedbush Maintains Outperform on The One Group Hospitality, Lowers Price Target to $7.5

By Benzinga Newsdesk

November 4, 3:10 PM

Wedbush analyst Nick Setyan maintains The One Group Hospitality (NASDAQ:STKS) with a Outperform and lowers the price target from $19 to $7.5.

STKS

US Producer Price Index Might Increase By This Much In September, Here Are The Major Macro Issues For Wednesday

By Lisa Levin

October 12, 4:21 AM

U.S. stocks closed mostly lower on Tuesday with the Nasdaq Composite dropping over 100 points amid a decline in Meta Platforms, Inc. (NASDAQ: META) shares.

U.S. Regulator Says Traffic Deaths Cost United States $340B In 2019

Related Posts

Discontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In Millions

What’s Going On With Stoke Therapeutics Stock Tuesday?

Wedbush Maintains Outperform on The One Group Hospitality, Lowers Price Target to $7.5

US Producer Price Index Might Increase By This Much In September, Here Are The Major Macro Issues For Wednesday